AU2020349002B2 - Stable, concentrated radiopharmaceutical composition - Google Patents

Stable, concentrated radiopharmaceutical composition Download PDF

Info

Publication number
AU2020349002B2
AU2020349002B2 AU2020349002A AU2020349002A AU2020349002B2 AU 2020349002 B2 AU2020349002 B2 AU 2020349002B2 AU 2020349002 A AU2020349002 A AU 2020349002A AU 2020349002 A AU2020349002 A AU 2020349002A AU 2020349002 B2 AU2020349002 B2 AU 2020349002B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
composition according
acid
salts
ascorbic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020349002A
Other languages
English (en)
Other versions
AU2020349002A1 (en
Inventor
Donato BARBATO
Lorenza Fugazza
Maurizio F. MARIANI
Francesca ORLANDI
Lorenzo SACCHETTI
Mattia TEDESCO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2020349002A1 publication Critical patent/AU2020349002A1/en
Application granted granted Critical
Publication of AU2020349002B2 publication Critical patent/AU2020349002B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020349002A 2019-09-16 2020-09-15 Stable, concentrated radiopharmaceutical composition Active AU2020349002B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19197607 2019-09-16
EP19197607.5 2019-09-16
PCT/EP2020/075767 WO2021052960A1 (en) 2019-09-16 2020-09-15 Stable, concentrated radiopharmaceutical composition

Publications (2)

Publication Number Publication Date
AU2020349002A1 AU2020349002A1 (en) 2022-04-28
AU2020349002B2 true AU2020349002B2 (en) 2024-05-02

Family

ID=67981980

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020349002A Active AU2020349002B2 (en) 2019-09-16 2020-09-15 Stable, concentrated radiopharmaceutical composition

Country Status (11)

Country Link
US (2) US20220401593A1 (https=)
EP (1) EP4031193A1 (https=)
JP (2) JP7762648B2 (https=)
KR (1) KR20220063218A (https=)
CN (1) CN114728088A (https=)
AR (1) AR119974A1 (https=)
AU (1) AU2020349002B2 (https=)
CA (1) CA3154302A1 (https=)
IL (1) IL291315A (https=)
TW (1) TW202123976A (https=)
WO (1) WO2021052960A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4442285A1 (en) * 2021-11-30 2024-10-09 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
JP2026505341A (ja) 2023-02-08 2026-02-13 ノバルティス アーゲー 神経膠芽腫を治療するための方法
IL322257A (en) 2023-02-23 2025-09-01 Novartis Ag Methods of treating breast cancer
CN121793988A (zh) 2023-09-13 2026-04-03 东丽株式会社 癌的治疗、预防和/或诊断用药物组合物
TW202527951A (zh) 2023-12-15 2025-07-16 瑞士商諾華公司 用於治療乳腺癌的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009393A2 (en) * 2003-07-24 2005-02-03 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for preparation
US20150265732A1 (en) * 2012-09-25 2015-09-24 Biosynthema Inc. Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009393A2 (en) * 2003-07-24 2005-02-03 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for preparation
US20150265732A1 (en) * 2012-09-25 2015-09-24 Biosynthema Inc. Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer

Also Published As

Publication number Publication date
AR119974A1 (es) 2022-01-26
EP4031193A1 (en) 2022-07-27
WO2021052960A1 (en) 2021-03-25
US20220401593A1 (en) 2022-12-22
JP2022548875A (ja) 2022-11-22
IL291315A (en) 2022-05-01
CN114728088A (zh) 2022-07-08
KR20220063218A (ko) 2022-05-17
TW202123976A (zh) 2021-07-01
US20250332301A1 (en) 2025-10-30
JP2026031934A (ja) 2026-02-25
AU2020349002A1 (en) 2022-04-28
JP7762648B2 (ja) 2025-10-30
CA3154302A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
AU2020349002B2 (en) Stable, concentrated radiopharmaceutical composition
TWI878344B (zh) 放射性標記grpr拮抗劑之方法及其套組
US20250170243A1 (en) Stable formulations for radionuclide complexes
WO2004069285A1 (en) Improved radiometal complex compositions
CN117159753A (zh) 放射性标记的伊文思蓝衍生物药物的制备方法及用途
AU2019289884B2 (en) Composition containing a somatostatin analogue for radiopharmaceutical use
CN118647415A (zh) 包含225锕标记的络合物和铋多价螯合剂的药物组合物
CA3103190A1 (en) Composition containing a somatostatin analogue for radiopharmaceutical use
JPH07505621A (ja) 外科手術中における腫瘍組織の検出および探知法
EP1192166B1 (en) Group(vii) transition-metal complexes with multidentate aminopolycarboxylate ligands and a kit for producing them
RU2839656C1 (ru) Стабильная концентрированная радиофармацевтическая композиция
US20250313579A1 (en) Ligand compounds comprising a chelating group as a bridging group
JP2003535005A (ja) 過テクネチウム酸塩および過レニウム酸塩の還元剤としてスズイオンを使用するＴｃおよびＲｅカルボニル錯体の処方
WO2023202730A2 (zh) 放射性伊文思蓝衍生物药物水溶液及其制备方法和用途
CN114796532A (zh) 放射性标记的伊文思蓝衍生物药物水溶液及其用途
RU2855011C1 (ru) Способы мечения радиоактивными изотопами антагонистов grpr и наборы на для их осуществления

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)